Precision BioSciences reports HBV clinical milestone
PBGENE-HBV achieved first biopsy evidence of cccDNA elimination, while the company reported Q2 2026 results and a cash balance of $112.4 million.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day